US$ 22.45
glp-1/gip agonists Schematic illustration of monoagonists, dual and triple Frontiers | Mechanisms of action
Description
Published 2021-5-11 Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure

doi: 10.1007/s11695-021-05394-x [DOI] [PubMed] [Google Scholar] 20.Voorwinde V, Hoekstra T, Monpellier VM, Steenhuis IHM, Janssen IMC, van Stralen MM

The findings revealed that GLP1RAs could extend 6MWT and lower the risk of HF hospitalization in people without a history of HF
Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved these agents for glycaemic control in type 2 diabetes and, in specific formulations and doses (semaglutide as Wegovy and liraglutide as Saxenda), for weight management in adults with obesity or overweight with weight-related comorbidities

The brain regions (e.g., NST) responsible for mediating the inhibitory effect of GLP-1 on gastric emptying depend on intact vagal afferent input
